medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 1

<< Back Next >>

Ann Hepatol 2011; 10 (1)

Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature

Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L

Language: English
References: 35
Page: 93-98
PDF size: 173.23 Kb.


ABSTRACT

Flutamide is a non-steroidal anti-androgenic drug, commonly used in the treatment of advanced prostate cancer, acne and hirsutism. This drug may induce various degrees of liver injury, including acute liver failure (ALF), with further need for liver transplantation. Here, we present a report of 10 consecutive patients seen in a period of 14 years, with acute liver toxicity induced by flutamide (in most cases severe hepatotoxicity): 3 men and 7 women, with a mean age of 75 and 29 years old, respectively. All men received flutamide as treatment of advanced prostate carcinoma and they developed hepatotoxicity without ALF, and three months after withdrawal of the drug, they recovered completely. In contrast, in 7 young female with liver toxicity caused by flutamide as treatment of various hyperandrogenic conditions (acne and hirsutism), ALF was observed in 5 patients, all of them requiring urgent liver transplantation, with excellent outcome and survival in 4 of them. Based on the above, we believe that flutamide treatment should be preferentially avoided in young female patients with benign pathologies, or if it is used, patients should be warned of its potential severe complications. Also, serial liver tests should be closely monitored and, in case of elevations, the drug should be immediately withdrawn.


REFERENCES

  1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 1989; 321: 419-24.

  2. Rittmaster RS. Hirsutism. Lancet 1997; 349: 191-5.

  3. Cassero-Branco C, Moyano D, Gómez O, Baasch J. Longterm safety and tolerability of flutamide for the treatment of hirsutism. Fertil Steril 2009; 91: 1183-8.

  4. Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: Data from the spanish pharmacovigilance system. Pharmaco Epidemiol Drug Saf 2006; 15: 253-9.

  5. Cetin M, Demirci D, Unal A, Altinbas M, Guven M, Uluhizarci K. Frequency of flutamide induced hepatotoxicity in patients with prostatic carcinoma. Hum Exp Toxicol 1999; 18: 137-40.

  6. Brodgen RN, Clissold SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 1989; 38: 185-203.

  7. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. Hepatology 1997; 26: 664-9.

  8. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9.

  9. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-85.

  10. Pu YS, Liu CM, Kao JH, Chen J, Laim MK. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur Urol 1999; 36: 293-7.

  11. Hart W, Strickr BH. Flutamide and hepatitis [letter]. Ann Intern Med 1989; 110: 943-4.

  12. Moller S, Iversen P, Franzmann MB. Flutamide-induced liver failure. J Hepatol 1990; 10: 346-9.

  13. Coppere H, Perrud Y, Gerard F, Jouffre C, David A, Barthelemy C, et al. Un cas d‘hepatite aigue au flutamide. [A case of acute hepatitis caused by flutamide (Letter)]. Gastroenterol Clin Biol 1990; 14: 105-6.

  14. Alperine M, Cohen L, Cocheton JJ, Lecomte I, Meyniel D. Hepatite aigue due au flutamide (acute hepatitis caused by flutamide) [Letter]. Presse Med 1991; 20: 1459-60.

  15. Corkery JC, Bihrle W 3rd, McCaffrey JA, Whitcomb FF, Levy C, Ellis R. Flutamide-related fulminant hepatic failure [Letter]. J Clin Gastroenterol 1991; 13: 364-5.

  16. Gomez JL, Dupont A, Cusan L, Tremblay M, Subruv R, Lemay M, et al. Incidence of liver toxicity associated with the use of flutamide on prostate cancer patients. Am J Med 1992; 92: 465-70.

  17. Wysowski DK, Feiman JP, Tourtelot JB, Horton LM. Fatal and non fatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118: 860-4.

  18. Muderris II, Bayram F, Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 2000; 14: 38-41.

  19. Ibañez L, Valls C, Cabré S, Zegher F. Flutamide-metformin plus ethilnylestradiol-diopirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low dose flutamide. J Clin Endocrinol Metab 2004; 89: 4716-20.

  20. Ibañez L, Zegher F. Ethinylestradio-drospirenone, flutamide- metformin, or both for adolescents and young women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89: 1592-7.

  21. Ibañez L, Zegher F. Flutamide-metformin plus ethinylestradio- dropirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin and the start and after more than one year of therapy. J Clin Endocrinol Metab 2005; 90: 39-43.

  22. Ibáñez L, Jaramillo A, Ferrer A, de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 2005; 20: 1833-6.

  23. Chung CY, Schiano TD. Drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25: 1135-51.

  24. Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. World J Gastroenterol 2007; 13: 329-34.

  25. Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 2007; 11: 459-75.

  26. Fau D, Eugene D, Berson A, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994; 269: 954-62.

  27. Pauli-Magnus C, Meier PJ, Stieger B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin Liver Dis 2010; 30: 147-59.

  28. Strnad P, Zhou Q, Hanada S, Lazzeroni LC, Zhong BH, So P, Davern TJ, Lee WM. Acute Liver Failure Study Group, Omary MB. Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology 2010; 139: 828-35.

  29. Daly K. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010; 11: 607-11.

  30. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009; 29: 400-211.

  31. Caballería E, Aragó JU, Sanchis A. Hepatotoxicity due to flutamide. Med Clin 1994; 102: 434-8.

  32. Lübert C, Wiese M, Haupt R, Ruf RQ. Toxic hepatitis and liver failure under therapy with flutamide. Internist 2004; 45: 333-40.

  33. García-Cortes M, Andrade RJ, Lucena MI, Sanchez-Martinez H, Fernandez MC, Ferrer T, et al. Flutamide-induced hepatotoxiciy: report of a case series. Rev Esp Enferm Dig 2001; 93: 423-32.

  34. Fernández CM, Morano LE, Montes J, Fachal C. Fallo hepático fulminante con evolución fatal inducido por flutamida. Med Clin 1997; 108: 237-8.

  35. Dourakis SP, Alexopoulou AA, Hadziyannis SJ. Fulminant hepatitis after flutamide treatment. J Hepatol 1994; 20: 350-3.




2020     |     www.medigraphic.com